Market
Which regulatory body will approve Zepbound next after the FDA by end of 2025?
2
Resolution / Starting Odds
European Medicines Agency (EMA) • 25%
Medicines and Healthcare products Regulatory Agency (MHRA) • 25%
Therapeutic Goods Administration (TGA) • 25%
Other • 25%
Approval announcements from regulatory bodies such as EMA, MHRA, or TGA
Story
Eli Lilly's Zepbound Surpasses Novo Nordisk's Wegovy in 72-Week SURMOUNT-5 Trial
Dec 4, 2024, 12:04 PM
In a significant development in the pharmaceutical industry, Eli Lilly & Co.'s obesity drug Zepbound (tirzepatide) has outperformed Novo Nordisk A/S's Wegovy (semaglutide) in the SURMOUNT-5 head-to-head clinical trial. Over 72 weeks, participants using Zepbound achieved an average weight loss of 20.2% (50.3 lbs or 22.8 kg), compared to 13.7% (33.1 lbs or 15.0 kg) for those on Wegovy, representing a 47% greater relative weight reduction. The trial involved adults with obesity or overweight conditions, along with related diseases such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease, but without type 2 diabetes. The results have led to a rise in Eli Lilly's stock, highlighting the competitive edge Zepbound has in the weight loss drug market.
View original story
Similar markets
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
Yes • 50%
No • 50%
5 to 10 • 25%
More than 15 • 25%
11 to 15 • 25%
Less than 5 • 25%
US SEC • 25%
European Central Bank • 25%
BaFin (Germany) • 25%
Other • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
20 to 40 • 25%
More than 60 • 25%
40 to 60 • 25%
Less than 20 • 25%
500,000 to 1 million • 25%
More than 2 million • 25%
1 million to 2 million • 25%
Less than 500,000 • 25%